Clinical trials: Atopic Dermatitis (AD), active
Eczema Atopic Dermatitis, Eczema
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis…
- Conditions
- Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
- Trial name
- GX-03 in AD (NCT07355075)
- Testing
- GX-03, Vehicle
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Turn Therapeutics
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
- Trial name
- PROSE (NCT03428646)
- Testing
- Dupilumab
- Where
- 99 sites in United States, Canada
- Volunteers
- 858 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease…
- Trial name
- PROADAP (NCT06415175)
- Testing
- Dupilumab
- Where
- 15 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study of TAVO101 in Atopic Dermatitis Patients
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
- Trial name
- NCT06176040
- Testing
- TAVO101
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Tavotek Biotherapeutics
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT07239947
- Testing
- BBT001
- Where
- 10 sites in China
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Atopic Dermatitis (AD)
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)
- Trial name
- NCT07184645
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 198 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD).
- Trial name
- FRAME (NCT06837454)
- Where
- 61 sites in France
- Volunteers
- 600 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population
The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of…
- Trial name
- AD-GMP-SCORAD (NCT07259343)
- Testing
- glycomacropeptide, emollient cream
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Universidad Autónoma de Aguascalientes
Atopic Dermatitis (AD), Autoantibody
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or…
- Conditions
- Atopic Dermatitis (AD), Autoantibody, Auto-Immunity, Microbiome, Human
- Trial name
- DIANA (NCT07316465)
- Testing
- Development of atopic dermatitis with/without IgE autoantibodies
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Dermatitis, Atopic
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT07042126
- Testing
- 611
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis (AD), Psoriasis (PsO)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.
- Trial name
- NCT06982352
- Testing
- LPX-TI641
- Where
- 3 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis…
- Trial name
- NCT06808477
- Testing
- BBT001
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Atopic Dermatitis
Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study
- Trial name
- NCT04730024
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis, Eczema
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy.
- Trial name
- PROTECT (NCT05938478)
- Testing
- Tralokinumab
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of California, San Diego
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi